Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 2/20 | 0.76 |
| ▸ | CDK4 | P11802 | 2/20 | 0.76 |
| ▸ | CCND1 | P24385 | 2/20 | 0.76 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.76 |
| ▸ | CDK2 | P24941 | 2/20 | 0.76 |
| ▸ | PIM1 | P11309 | 2/20 | 0.76 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.76 |
| ▸ | PRKCA | P17252 | 1/20 | 0.72 |
| ▸ | PRKACA | P17612 | 1/20 | 0.72 |
| ▸ | PRKACG | P22612 | 1/20 | 0.72 |
| ▸ | PRKACB | P22694 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30319841 | 1.00 | CCNE2 (0.76) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL8161322 | 0.88 | CCNE2 (0.74) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL28912765 | 0.88 | CCNE2 (0.74) | CCNE2CDK4CCND1CCNE1CDK2 | |
| Hydrochloric Acid SCHEMBL8163206 | 0.88 | PIM1 (0.86) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL30319849 | 0.87 | CCNE2 (1.00) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL5686048 | 0.87 | CCNE2 (1.00) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL8162785 | 0.86 | PIM1 (0.79) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL8122815 | 0.86 | PRKCA (0.87) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL8161666 | 0.86 | PIM1 (0.78) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL3139598 | 0.86 | GSK3B (0.78) | CCNE2CDK4CCND1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | claimed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | claimed |
| US-20150087687-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS (US) | 2015-03-26 | — | — | US | claimed |
| EP-2827869-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | Brown, Dennis (US) | 2015-01-28 | — | — | EP | claimed |
| WO-2013142817-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS (US) | 2013-09-26 | — | — | WO | claimed |
| US-20060217368-A1 | Drug for nerve regeneration | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-28 | — | — | US | claimed |
| EP-1645286-A1 | DRUG FOR NERVE REGENERATION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-04-12 | — | — | EP | claimed |
| EP-1140070-A1 | TREATMENT OF CONDITIONS WITH A NEED FOR THE INHIBITION OF GSK-3 | SMITHKLINE BEECHAM PLC (GB) | 2001-10-10 | — | — | EP | claimed |
| WO-2000038675-A1 | TREATMENT OF CONDITIONS WITH A NEED FOR THE INHIBITION OF GSK-3 | SMITHKLINE BEECHAM PLC (GB) | 2000-07-06 | — | — | WO | claimed |
| US-20230100193-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | CYTODIGM, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20200383931-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | CYTODIGM, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | disclosed |
| EP-3600259-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | Phosphorex, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| CN-110709066-A | Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same | 法斯瑞斯公司 | 2020-01-17 | — | — | CN | disclosed |
| WO-2005028678-A9 | METHODS AND MATERIALS FOR IDENTIFYING AGENTS WHICH MODULATE BONE REMODELING AND AGENTS IDENTIFIED THEREBY | WYETH CORP (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-1645286-A1 | DRUG FOR NERVE REGENERATION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-04-12 | — | — | EP | disclosed |
| EP-1636388-A2 | METHODS AND MATERIALS FOR IDENTIFYING AGENTS WHICH MODULATE BONE REMODELING AND AGENTS IDENTIFIED THEREBY | Wyeth (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005028678-A2 | METHODS AND MATERIALS FOR IDENTIFYING AGENTS WHICH MODULATE BONE REMODELING AND AGENTS IDENTIFIED THEREBY | WYETH (US) | 2005-03-31 | — | — | WO | disclosed |
| EP-1140070-A1 | TREATMENT OF CONDITIONS WITH A NEED FOR THE INHIBITION OF GSK-3 | SMITHKLINE BEECHAM PLC (GB) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000038675-A1 | TREATMENT OF CONDITIONS WITH A NEED FOR THE INHIBITION OF GSK-3 | SMITHKLINE BEECHAM PLC (GB) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230100193-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | UGT2B7, UGT1A7, CYP3A7 | CCNE2 1433/4885CDK4 1568/4885CCND1 2968/4885 |
| US-20060217368-A1 | Drug for nerve regeneration | GSK3A, BDNF, GSK3B | CCNE2 2297/4885CDK4 85/4885CCND1 1989/4885 |
| US-20200383931-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | UGT2B7, UGT1A7, CYP3A7 | CCNE2 1433/4885CDK4 1568/4885CCND1 2968/4885 |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | CCNE2 2620/4885CDK4 689/4885CCND1 2386/4885 |
| US-20150087687-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | CYP7A1, CYP3A7, UGT2B7 | CCNE2 2755/4885CDK4 1596/4885CCND1 3364/4885 |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | CCNE2 2620/4885CDK4 689/4885CCND1 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.